At the American Cardiology Congress (ACC) this week in New Orleans, the market leading Transcatheter Aortic Valve Replacement (TAVR) companies presented their data comparing TAVR to Surgery.
In this data one trial showed 1400 patients being followed up for 24 months, TAVR was noninferior to SAVR for mortality/disabling stroke for treatment of severe symptomatic aortic stenosis (AS) in low-risk patients. In another trial, also with low-risk AS patients, TAVR was superior to SAVR at preventing death, stroke, or rehospitalization at 1 year. TAVR was also associated with a lower incidence of stroke and atrial fibrillation, and a shorter hospital length of stay compared with SAVR. In both trials it was noted that Long term outcomes and valve durability yet needs to be established, but future research is already planned.
The impact of this new data means that TAVR manufacturers need to prove that their valve will be durable over the long term (free from calcification) as significantly younger patients will now potentially be eligible for a TAVR.
This data also highlights that the number of AS patients across the treatment spectrum that can benefit from TAVR will potentially double according to Credit Suisse.
At present, in Cardiac Surgery the Admedus ADAPT Tissue Technology is the first and only scaffold clinically proven not to calcify partly due to its zero DNA profile.